What is the 13F Pro Quality Score for PCVX?

13F Pro ranks Vaxcyte, Inc. (PCVX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PCVX's current score at https://13fpro.ai/research/PCVX (free sign-up required for the full ranking).

Which hedge funds own the most PCVX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PCVX include JANUS HENDERSON GROUP PLC, FMR, RA CAPITAL MANAGEMENT, L.P.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PCVX as soon as new 13F filings post.

Where does 13F Pro source PCVX data?

All Vaxcyte, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vaxcyte, Inc. files with the SEC under CIK 1649094. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PCVX in?

Vaxcyte, Inc. (PCVX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PCVX research updated on 13F Pro?

PCVX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vaxcyte, Inc.(PCVX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1649094 PCVX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PCVX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vaxcyte, Inc. (PCVX), a Healthcare sector company. PCVX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Vaxcyte, Inc. reports net income of $-320.6M, free cash flow of $-282.7M. Top institutional holders of PCVX by reported 13-F value include JANUS HENDERSON GROUP PLC, FMR, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. PCVX trades on the Nasdaq exchange and files with the SEC under CIK 1649094. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PCVX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vaxcyte, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-320.6M

Free Cash Flow

Q1 2026

$-282.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-190477.4% YoY

$-766.6MFY 2025

FY21 $-100.1KFY22 $-223.5MFY23 $-402.3KFY25 $-766.6M

Operating Income

-97.3% YoY

$-923.7MFY 2025

FY21 $-103.7MFY22 $-232.3MFY23 $-468.0MFY25 $-923.7M

EPS (Diluted)

-36.0% YoY

$-5.63FY 2025

FY21 $-1.93FY22 $-3.44FY23 $-4.14FY25 $-5.63

Total Assets

+113.3% YoY

$3.00BFY 2025

FY21 $324.3MFY22 $1.01BFY23 $1.41BFY25 $3.00B

Op. Cash Flow

-120.9% YoY

$-655.6MFY 2025

FY21 $-121.4MFY22 $-170.6MFY23 $-296.8MFY25 $-655.6M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-766.6M -190477.4%	$-402.3K +99.8%	$-223.5M -223213.0%	$-100.1K +99.9%	$-89.2M -77.5%	$-50.3M
Operating Income	$-923.7M -97.3%	$-468.0M -101.5%	$-232.3M -124.0%	$-103.7M -15.7%	$-89.6M -65.4%	$-54.2M
EPS (Diluted)	$-5.63 -36.0%	$-4.14 -20.3%	$-3.44 -78.2%	$-1.93 +36.1%	$-3.02	—
Total Assets	$3.00B +113.3%	$1.41B +39.9%	$1.01B +210.2%	$324.3M -17.4%	$392.8M +497.9%	$65.7M
Operating Cash Flow	$-655.6M -120.9%	$-296.8M -74.0%	$-170.6M -40.5%	$-121.4M -160.3%	$-46.6M +1.1%	$-47.1M

AI Insight: PCVX Financial Trends

Vaxcyte's cash burn and operating losses accelerated sharply in Q1 2026, with operating cash outflow reaching $281M and net loss widening to $321M.

• Operating losses deteriorated from $153M in Q2 2024 to $346M in Q1 2026, a 126% decline over 9 quarters.

• Operating cash burn worsened from $121M in Q2 2024 to $281M in Q1 2026, reflecting accelerating cash consumption.

• Equity declined from $3,418M in Q3 2024 to $2,996M in Q1 2026, eroding shareholder value amid ongoing losses.

⚠ Q1 2026 marks largest quarterly net loss ($321M) and operating cash burn ($281M) in dataset; trajectory unsustainable.

⚠ Equity rebounded $303M Q4 2025 to Q1 2026 despite record losses—potential capital raise or accounting adjustment requires clarification.

AI Insight: PCVX Ratio Trends

Vaxcyte's returns have deteriorated sharply across all metrics, with Q1 2026 ROE, ROA, and ROIC all reaching new lows of -42.8%, -38.3%, and -46.2% respectively.

• ROE collapsed from -25.9% in Q2 2024 to -42.8% in Q1 2026, a 17pp deterioration over nine quarters.

• ROIC worsened from -30.8% in Q2 2024 to -46.2% in Q1 2026, indicating increasingly negative capital deployment.

• Every quarterly return metric has declined consecutively since Q3 2024, with no stabilization or recovery.

⚠ Q1 2026 marks the worst quarterly performance across ROE, ROA, ROIC—monitor next quarter for any inflection or continued deterioration.

⚠ Sustained negative returns suggest operating losses are widening; lack of OpMargin/NPM data limits visibility into cash burn trajectory.

Get alerted when PCVX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vaxcyte, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PCVX

JANUS HENDERSON GROUP PLC
$960.2M16,575,875 sh
FMR LLC
$958.4M16,492,861 sh
RA CAPITAL MANAGEMENT, L.P.
$666.8M11,474,599 sh
BlackRock, Inc.
$637.6M10,971,816 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$364.9M6,279,545 sh
VANGUARD CAPITAL MANAGEMENT LLC
$364.2M6,266,701 sh
WELLINGTON MANAGEMENT GROUP LLP
$326.3M5,614,597 sh
Paradigm Biocapital Advisors LP
$278.5M4,793,020 sh
STATE STREET CORP
$258.0M4,440,519 sh
Deep Track Capital, LP
$249.9M4,300,000 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$960.2M	16,575,875
FMR LLC	$958.4M	16,492,861
RA CAPITAL MANAGEMENT, L.P.	$666.8M	11,474,599
BlackRock, Inc.	$637.6M	10,971,816
VANGUARD PORTFOLIO MANAGEMENT LLC	$364.9M	6,279,545
VANGUARD CAPITAL MANAGEMENT LLC	$364.2M	6,266,701
WELLINGTON MANAGEMENT GROUP LLP	$326.3M	5,614,597
Paradigm Biocapital Advisors LP	$278.5M	4,793,020
STATE STREET CORP	$258.0M	4,440,519
Deep Track Capital, LP	$249.9M	4,300,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PCVX on your watchlist

Track score changes the day Vaxcyte, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PCVX a good stock to buy?

13F Pro's AI-powered analysis of Vaxcyte, Inc. (PCVX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PCVX are available on the PCVX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PCVX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PCVX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vaxcyte, Inc.'s investment landscape.